Synergistic polymorphisms of β 1- and α 2C-adrenergic receptors and the risk of congestive heart failure

New England Journal of Medicine

Volumn 347, Issue 15, 2002, Pages 1135-1142

  Small, Kersten M ^a   Wagoner, Lynne E ^b   Levin, Albert M ^c   Kardia, Sharon L R ^d   Liggett, Stephen B ^c,d  

^a Division of Pulmonary Medicine

^b Department of Cardiology ^*

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; NORADRENALIN; ADRENERGIC RECEPTOR ALPHA(2C);

ADRENERGIC STIMULATION; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSFECTION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CELL; NEGATIVE FEEDBACK; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RISK FACTOR; TANDEM REPEAT; CASE CONTROL STUDY; CAUCASIAN; ETHNOLOGY; GENETICS; METABOLISM; MIDDLE AGED; NEGRO; RISK; STATISTICAL MODEL; SURVIVAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NOREPINEPHRINE; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-1; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0037057235     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020803     Document Type: Article

References (29)

1. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998;352:Suppl 1:SI-8-SI-14.
2. Idem. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail 2000;6:Suppl 1:8-14.
3. Liggett SB. β-Adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest 2001;107:947-8.
4. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1988;35:295-303.
5. Packer M. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. Eur Heart J 1998;19: Suppl B:B40-B46.
6. Liggett SB, Shah SD, Cryer PE. Human tissue adrenergic receptors are not predictive of responses to epinephrine in vivo. Am J Physiol 1989;256: E600-E609.
7. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 1998;32:Suppl 1: S31-S35.
8. Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoreceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001;37:1246-51.
9. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402:181-4.
10. 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-64.
11. Minatoguchi S, Ito H, Ishimura K, et al. Modulation of noradrenaline release through presynaptic alpha 2-adrenoceptors in congestive heart failure. Am Heart J 1995;130:516-21.
12. Parker JD, Newton GE, Landzberg JS, Floras JS, Colucci WS. Functional significance of presynaptic alpha-adrenergic receptors in failing and nonfailing human left ventricle. Circulation 1995;92:1793-800.
13. 1-adrenergic receptor. J Biol Chem 1999;274:12670-4.
14. Small KM, Rathz DA, Liggett SB. Identification of adrenergic receptor polymorphisms. Methods Enzymol 2002;343:459-75.
15. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-8.
16. Sacchetti L, Calcagno G, Coto I, Tinto N, Vuttariello E, Salvatore F. Efficiency of two different nine-loci short tandem repeat systems for DNA typing purposes. Clin Chem 1999;45:178-83.
17. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
18. 1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 1999;14:271.
19. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87:Suppl VI:VI-5-VI-16.
20. Friddie CJ, Koga T, Rubin EM, Bristow J. Expression and profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci U S A 2000;97:6745-50.
21. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000;32:817-30.
22. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-64.
23. Bourne HR. How receptors talk to trimeric G proteins. Curr Opin Cell Biol 1997;9:134-42.
24. Liggett SB. Plastic adenylyl cyclase. Am J Respir Cell Mol Biol 1999;21:564-6.
25. Zhang Y-H, Zhu J, Song Y-C. Suppressing sympathetic activation with clonidine on ventricular arrhythmias in congestive heart failure. Int J Cardiol 1998;65:233-8.
26. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension 2001;38:286-91.
27. Hermiller JB, Magorien RD, Leithe ME, Unverferth DV, Leier CV. Clonidine in congestive heart failure: a vasodilator with negative inotropic effects. Am J Cardiol 1983;51:791-5.
28. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL. Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther 1981;30:724-8.
29. Manolis AJ, Olympios C, Sifaki M, et al. Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. Hypertension 1995;26:719-24.